When Jefferies released a research note for Arena Pharmaceuticals (ARNA) with a target price of $12, shares subsequently fell to around $6.90 since the analysis. Similar to other pharmaceutical plays, Arena traded higher ahead of the release of weight-loss drug Belviq on the market. Obesity is a growing problem, and Belviq has a large market to address, but whether the value of the company will be driven upwards depends on a few key results.
[Read more from Kapitall: 6 Cash-Rich Healthcare Stocks Look Undervalued]
Results to Watch
Investors should watch the following before asserting a more positive sentiment on Arena:1. Weekly prescriptions for Belviq 2. Effective advertising 3. Rising coverage for Belviq from insurance companies In the near term, short sellers could dictate the depressed share price for Arena. Short float is around 28%. Bets against Arena have risen steadily since April. The only time short selling declined was between April 15 and April 30, 2013: Alternative Investments Vivus (VVUS) is often considered as an alternative investment to Arena. Bearishness for Vivus is also high, with short float at 29.4%. Vivus recently released Qsymia, and scripts for the obesity drug could be growing. Regardless of the actual rate of prescriptions, both Qsymia and Belviq should experience stronger sales in the future. It takes time for the market to gain acceptance of a new drug in the market. Other companies in the pharmaceutical space to research are illustrated in the chart below: &amp;amp;amp;amp;amp;amp;amp;lt;p&amp;amp;amp;amp;amp;amp;amp;gt;Your browser does not support iframes.&amp;amp;amp;amp;amp;amp;amp;lt;/p&amp;amp;amp;amp;amp;amp;amp;gt; Disclosure: Author has a long position in Arena Pharmaceuticals Written by Chris Lau, Kapitall contributor. Monthly returns sourced from Zacks Investment Research.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV